JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on June 12, 2003; DOI: 10.1124/jpet.103.049429


0022-3565/03/3063-1129-1136$20.00
JPET 306:1129-1136, 2003
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.049429v1
306/3/1129    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hajela, R. K.
Right arrow Articles by Atchison, W. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hajela, R. K.
Right arrow Articles by Atchison, W. D.

TOXICOLOGY

Comparative Effects of Methylmercury and Hg2+ on Human Neuronal N- and R-Type High-Voltage Activated Calcium Channels Transiently Expressed in Human Embryonic Kidney 293 Cells

Ravindra K. Hajela1, Shuang-Qing Peng1, and William D. Atchison

Department of Pharmacology and Toxicology, Institute of Environmental Toxicology and Neuroscience Program, Michigan State University, East Lansing, Michigan

Expression cDNA clones of {alpha}1B-1 or {alpha}1E-3 subunits coding for human neuronal N-(Cav2.2) or R-subtype (Cav2.3) Ca2+ channels, respectively, was combined with {alpha}2-b{delta} and {beta}3-a Ca2+ channel subunits, and transfected into human embryonic kidney cells for transient expression to determine whether specific types of neuronal voltage-sensitive Ca2+ channels are affected differentially by methylmercury (MeHg) and Hg2+. For both Ca2+ channel subtypes, MeHg (0.125-5.0 µM) or Hg2+ (0.1-5 µM) caused a time- and concentration-dependent reduction of current. MeHg caused an initial, rapid component and a subsequent more gradual component of inhibition. The rapid component of block was completed between 100 and 150 s after beginning treatment. At 0.125 to 1.25 µM, MeHg caused a more gradual decline in current. Apparent IC50 values were 1.3 and 1.1 µM for MeHg, and 2.2 and 0.7 µM for Hg2+ on N- and R-types, respectively. For N-type current, effects of Hg2+ were initially greater on the peak current than on the sustained current remaining at the end of a test pulse; subsequently, Hg2+ blocked both components of current. For R-type current, Hg2+ affected peak and sustained current approximately equally. Kinetics of inactivation also seemed to be affected by Hg2+ in cells expressing N-type but not R-type current. Washing with MeHg-free solution could not reverse effects of MeHg on either type of current. The effect of Hg2+ on N- but not R-type current was partially reversed by Hg2+-free wash solution. Therefore, different types of Ca2+ channels have differential susceptibility to neurotoxic mercurials even when expressed in the same cell type.


Received for publication January 22, 2003
Accepted May 23, 2003.

Address correspondence to: Dr. Bill Atchison, Department of Pharmacology and Toxicology, Michigan State University, B-331 Life Sciences Bldg., East Lansing, MI 48824-1317. E-mail: atchiso1{at}msu.edu




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
B. Tarabova, M. Kurejova, Z. Sulova, M. Drabova, and L. Lacinova
Inorganic Mercury and Methylmercury Inhibit the Cav3.1 Channel Expressed in Human Embryonic Kidney 293 Cells by Different Mechanisms
J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 418 - 427.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.